A Phase II Study of the Association of Glivec (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta [platelet derived growth factor receptor-beta] or C-Kit

Trial Profile

A Phase II Study of the Association of Glivec (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta [platelet derived growth factor receptor-beta] or C-Kit

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Imatinib (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top